Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Targeted Polymerized Shell Microbubbles to Image and Treat Surgical Adhesions

Award Number: R44GM116530
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2016
PERIOD OF PERFORMANCE END DATE: 02/28/2022

Group Awards By:

View Award Description

Targeted Polymerized Shell Microbubbles to Image and Treat Surgical Adhesions - Project Summary The long-term goal of this Phase II SBIR project is to develop a commercially viable ultrasound contrast reagent (UCR) that will allow the noninvasive identification and treatment of newly forming abdominal adhesions after surgery. Successful implementation would have significant impact because we would both improve patient post-surgical monitoring and considerably reduce the cost of adhesion related pathology on the health care system. Although surgical adhesions have “fallen under the radar” when it comes to public perception, their heavy impact on the United States health care system is undeniable. Roughly 7 million abdominal surgical procedures of all types are carried out annually, and almost 100% of these patients will develop adhesions. While most are asymptomatic, a significant number can lead to serious and even life-threatening complications. This Phase II investigation will build on our promising Phase I results defining a targeted polymerized shell microbubble (PSM) approach to imaging and treating adhesions. To successfully bring our technology closer to being commercially viable the aims include first optimizing and further characterizing our polymer-stabilized, adhesion-targeted, ultrasound microbubble model, followed by expanding our initial in vivo experiments to confirm their viability in both small and large animals. In our final aim, we intend to better understand and confirm our Phase I result in which we could show adhesion break-up in our rat model combining our targeted PSMs with non-invasive ultrasound irradiation. These further studies can confirm the viability of our technology moving it towards eventual clinical trials and commercial viability. This product would not only allow the early alleviation of potentially problematic adhesions, but also allow better monitoring of adhesion development and post-surgical recovery. Due to the huge magnitude of the problem, even a 50% reduction in post-surgical adhesions could save over $2.5 billion yearly in healthcare costs. !


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2019	NANOVALENT PHARMACEUTICALS INC	351 EVERGREEN DR	BOZEMAN	MT	59715	GALLATIN	USA	Biomedical Research and Research Training	000	3	10/27/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2019	NANOVALENT PHARMACEUTICALS, INC.	351 EVERGREEN DR STE B	BOZEMAN	MT	59715	GALLATIN	USA	Biomedical Research and Research Training	000	3	8/20/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2019	NANOVALENT PHARMACEUTICALS, INC.	351 EVERGREEN DR STE B	BOZEMAN	MT	59715	GALLATIN	USA	Biomedical Research and Research Training	000	3	10/29/2019	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $759,290 )
2019	2019	NANOVALENT PHARMACEUTICALS, INC.	351 EVERGREEN DR STE B	BOZEMAN	MT	59715	GALLATIN	USA	Biomedical Research and Research Training	001	3	8/28/2019	NON-COMPETING CONTINUATION	$759,290
2019	2018	NANOVALENT PHARMACEUTICALS, INC.	910 TECHNOLOGY BLVD STE G	BOZEMAN	MT	59718	GALLATIN	USA	Biomedical Research and Research Training	000	2	12/21/2018	COMPETING CONTINUATION	$0
														Subtotal = $759,290

Issue Date FY: 2018 ( Subtotal = $831,190 )
2018	2018	NANOVALENT PHARMACEUTICALS, INC.	910 TECHNOLOGY BLVD STE G	BOZEMAN	MT	59718	GALLATIN	USA	Biomedical Research and Research Training	000	2	8/29/2018	COMPETING CONTINUATION	$831,190
														Subtotal = $831,190

Grand Total All Awards = $1,590,480

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeted Polymerized Shell Microbubbles to Image and Treat Surgical Adhesions

Award Number: R44GM116530

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2016

PERIOD OF PERFORMANCE END DATE: 02/28/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer